Product
TAK-881
Aliases
Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase., Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20).
3 clinical trials
2 indications
Indication
Healthy Control ParticipantsIndication
Primary Immunodeficiency DiseasesClinical trial
A Phase 1, Single-Dose, Single-Center, Open-Label, Three-Arm Study to Assess the Tolerability and Safety of Immune Globulin Subcutaneous (Human), 20% Solution With Recombinant Human Hyaluronidase (TAK-881) at Various Infusion Rates in Healthy Adult SubjectStatus: Completed, Estimated PCD: 2022-04-12
Clinical trial
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)Status: Recruiting, Estimated PCD: 2026-02-10
Clinical trial
Long-term Safety and Tolerability of TAK-881 in Subjects With Primary Immunodeficiency Diseases (PIDD)Status: Not yet recruiting, Estimated PCD: 2027-05-07